|
1
|
Döhner H, Estey E, Grimwade D, Amadori S,
Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA,
et al: Diagnosis and management of AML in adults: 2017 ELN
recommendations from an international expert panel. Blood.
129:424–447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kell J: Considerations and challenges for
patients with refractory and relapsed acute myeloid leukaemia. Leuk
Res. 47:149–160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varnum BC, Young C, Elliott G, Garcia A,
Bartley TD, Fridell YW, Hunt RW, Trail G, Clogston C, Toso RJ, et
al: Axl receptor tyrosine kinase stimulated by the vitamin
K-dependent protein encoded by growth-arrest-specific gene 6.
Nature. 373:623–626. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Paccez JD, Vogelsang M, Parker MI and
Zerbini LF: The receptor tyrosine kinase Axl in cancer: Biological
functions and therapeutic implications. Int J Cancer.
134:1024–1033. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ben-Batalla I, Schultze A, Wroblewski M,
Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D,
Sawall S, et al: Axl, a prognostic and therapeutic target in acute
myeloid leukemia mediates paracrine crosstalk of leukemia cells
with bone marrow stroma. Blood. 122:2443–2452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hong CC, Lay JD, Huang JS, Cheng AL, Tang
JL, Lin MT, Lai GM and Chuang SE: Receptor tyrosine kinase AXL is
induced by chemotherapy drugs and overexpression of AXL confers
drug resistance in acute myeloid leukemia. Cancer Lett.
268:314–324. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Park IK, Mishra A, Chandler J, Whitman SP,
Marcucci G and Caligiuri MA: Inhibition of the receptor tyrosine
kinase Axl impedes activation of the FLT3 internal tandem
duplication in human acute myeloid leukemia: Implications for Axl
as a potential therapeutic target. Blood. 121:2064–2073. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park IK, Mundy-Bosse B, Whitman SP, Zhang
X, Warner SL, Bearss DJ, Blum W, Marcucci G and Caligiuri MA:
Receptor tyrosine kinase Axl is required for resistance of leukemic
cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia.
29:2382–2389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kariolis MS, Miao YR, Diep A, Nash SE,
Olcina MM, Jiang D, Jones DS II, Kapur S, Mathews II, Koong AC, et
al: Inhibition of the GAS6/AXL pathway augments the efficacy of
chemotherapies. J Clin Invest. 127:183–198. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kariolis MS, Miao YR, Jones DS II, Kapur
S, Mathews II, Giaccia AJ and Cochran JR: An engineered Axl ‘decoy
receptor’ effectively silences the Gas6-Axl signaling axis. Nat
Chem Biol. 10:977–983. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye X, Li Y, Stawicki S, Couto S,
Eastham-Anderson J, Kallop D, Weimer R, Wu Y and Pei L: An anti-Axl
monoclonal antibody attenuates xenograft tumor growth and enhances
the effect of multiple anticancer therapies. Oncogene.
29:5254–5264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Boshuizen J, Koopman LA, Krijgsman O,
Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper
K, Kuilman T, Song JY, et al: Cooperative targeting of melanoma
heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK
inhibitors. Nat Med. 24:203–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Duan Y, Hu B, Qiao C, Luo L, Li X, Wang J,
Liu H, Zhou T, Shen B, Lv M, et al: Engineered AXL-ECD-Fc variants
that abolish the AXL/Gas6 interaction suppress tumor cell
migration. Oncol Lett. 17:5784–5792. 2019.PubMed/NCBI
|
|
14
|
Duan Y, Luo L, Qiao C, Li X, Wang J, Liu
H, Zhou T, Shen B, Lv M and Feng J: A novel human anti-AXL
monoclonal antibody attenuates tumour cell migration. Scand J
Immunol. 90:e127772019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cossarizza A, Chang HD, Radbruch A, Acs A,
Adam D, Adam-Klages S, Agace WW, Aghaeepour N, Akdis M, Allez M, et
al: Guidelines for the use of flow cytometry and cell sorting in
immunological studies(second edition). Eur J Immunol. 49:1457–1973.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zou Y, Huang Y and Ma X: Phenylhexyl
isothiocyanate suppresses cell proliferation and promotes apoptosis
via repairing mutant P53 in human myeloid leukemia M2 cells. Oncol
Lett. 18:3358–3366. 2019.PubMed/NCBI
|
|
17
|
Zhao J, Song Y and Liu D: Gilteritinib: A
novel FLT3 inhibitor for acute myeloid leukemia. Biomark Res.
7:192019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Neubauer A, Fiebeler A, Graham DK, O'Bryan
JP, Schmidt CA, Barckow P, Serke S, Siegert W, Snodgrass HR and
Huhn D: Expression of axl, a transforming receptor tyrosine kinase,
in normal and malignant hematopoiesis. Blood. 84:1931–1941. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen Y, Chen X, He J, Liao D and Zu X: Axl
inhibitors as novel cancer therapeutic agents. Life Sci.
198:99–111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Francisco JA, Cerveny CG, Meyer DL, Mixan
BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki
BE, et al: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E
conjugate with potent and selective antitumor activity. Blood.
102:1458–1465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dornan D, Bennett F, Chen Y, Dennis M,
Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, et al:
Therapeutic potential of an anti-CD79b antibody-drug conjugate,
anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Blood. 114:2721–2729. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Naito K, Takeshita A, Shigeno K, Nakamura
S, Fujisawa S, Shinjo K, Yoshida H, Ohnishi K, Mori M, Terakawa S,
et al: Calicheamicin-conjugated humanized anti-CD33 monoclonal
antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on
CD33-positive leukemia cell lines, but is inactive on
P-glycoprotein-expressing sublines. Leukemia. 14:1436–1443. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsui H, Takeshita A, Naito K, Shinjo K,
Shigeno K, Maekawa M, Yamakawa Y, Tanimoto M, Kobayashi M, Ohnishi
K, et al: Reduced effect of gemtuzumab ozogamicin (CMA-676) on
P-glycoprotein and/or CD34-positive leukemia cells and its
restoration by multidrug resistance modifiers. Leukemia.
16:813–819. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen F, Song Q and Yu Q: Axl inhibitor
R428 induces apoptosis of cancer cells by blocking lysosomal
acidification and recycling independent of Axl inhibition. Am J
Cancer Res. 8:1466–1482. 2018.PubMed/NCBI
|
|
25
|
Jin Y, Nie D, Li J, Du X, Lu Y, Li Y, Liu
C, Zhou J and Pan J: Gas6/AXL signaling regulates self-renewal of
chronic myelogenous leukemia stem cells by stabilizing β-catenin.
Clin Cancer Res. 23:2842–2855. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang J, Li Y, Wang P, Han G, Zhang T,
Chang J, Yin R, Shan Y, Wen J, Xie X, et al: Leukemogenic Chromatin
Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL
Signaling Axis. Cell Stem Cell. 27:81–97.e8. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dumas PY, Naudin C, Martin-Lannerée S,
Izac B, Casetti L, Mansier O, Rousseau B, Artus A, Dufossée M,
Giese A, et al: Hematopoietic niche drives FLT3-ITD acute myeloid
leukemia resistance to quizartinib via STAT5-and hypoxia-dependent
upregulation of AXL. Haematologica. 104:2017–2027. 2019. View Article : Google Scholar : PubMed/NCBI
|
